Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort

Paul Kwo, Michael W. Fried, K. Rajender Reddy, Consuelo Soldevila‐Pico, Saro Khemichian, Jama Darling, Phillippe J. Zamor, Andrew A. Napoli, Beatrice Anduze‐Faris, Robert S. Brown – 27 February 2018 – We report the findings of an early access program providing treatment for chronic hepatitis C virus infection (any genotype) with daclatasvir and sofosbuvir with/without ribavirin to patients with Child‐Pugh class C cirrhosis or prior liver transplant recipients with recurrent hepatitis C virus infection and advanced fibrosis/cirrhosis.

Intestine farnesoid X receptor agonist and the gut microbiota activate G‐protein bile acid receptor‐1 signaling to improve metabolism

Preeti Pathak, Cen Xie, Robert G. Nichols, Jessica M. Ferrell, Shannon Boehme, Kristopher W. Krausz, Andrew D. Patterson, Frank J. Gonzalez, John Y.L. Chiang – 27 February 2018 – Bile acids activate farnesoid X receptor (FXR) and G protein–coupled bile acid receptor‐1 (aka Takeda G protein–coupled receptor‐5 [TGR5]) to regulate bile acid metabolism and glucose and insulin sensitivity. FXR and TGR5 are coexpressed in the enteroendocrine L cells, but their roles in integrated regulation of metabolism are not completely understood.

Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy

Jia‐Feng Wu, Chee‐Seng Lee, Wen‐Hsi Lin, Yung‐Ming Jeng, Huey‐Ling Chen, Yen‐Hsuan Ni, Hong‐Yuan Hsu, Mei‐Hwei Chang – 27 February 2018 – We investigated the utility of transient elastography (TE) for diagnosing biliary atresia (BA) in cholestatic infants and predicting the outcome of BA. Forty‐eight cholestatic infants (9‐87 days of age) with direct bilirubin level >1 mg/dL were enrolled. Liver stiffness measurement (LSM) by TE was performed during the cholestasis workup, and 15 subjects were diagnosed as BA.

Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta‐analysis

Yao‐Yao Zhou, Xiao‐Dong Zhou, Sheng‐Jie Wu, Dan‐Hong Fan, Sven Poucke, Yong‐Ping Chen, Shen‐Wen Fu, Ming‐Hua Zheng – 26 February 2018 – Nonalcoholic fatty liver disease (NAFLD) is associated with an increased risk of atherosclerotic cardiovascular disease. In our meta‐analysis, we aimed to assess the correlation of NAFLD and four surrogate markers of subclinical atherosclerosis. PubMed, Embase, and the Cochrane Library were searched up until April 2017. Original studies investigating the association between NAFLD and subclinical atherosclerosis were included.

Subscribe to